nivolumab,ipilimumab
bms
['ipi +', 'nivo', 'nsclc', ' ipi ', 'sclc', 'increase,(-increased)']
the increase trial combining ipi + nivo w/concurrent chemordt as induction therapy for pot. resectable nsclc (up to t4n2) enriched in pd-l1 high population #esmo2022 pcr 63% mpr 79%, a potential strategy in high risk patients? is rdt needed in light of noady chemo-io? 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC) ????. Implementing precision medicine programs in LATAM with PxMedica